Background. The pancreatic endocrine system normally guarantees a quick and efficient response to daily metabolic perturbations, but associated data for human immunodeficiency virus (HIV)-infected patients are lacking. A prospective study was performed to evaluate pancreatic endocrine secretion and its possible association with failure to thrive among HIV-infected children.
On a day-to-day basis, energy and protein metabolism are controlled by the secretory activity of the endocrine pancreas [1] . Although metabolic alterations have been widely reported to occur among HIV-infected individuals [2, 3] , a detailed characterization of the pancreatic endocrine system in HIV-infected subjects is still lacking. Behrens et al. [4] recently reported b cell dysfunction in HIV-infected individuals, but their findings referred only to adult patients who were receiving treatment with protease inhibitors. Therefore, a prospective study was performed with the aim of evaluating pancreatic endocrine activity, its influence on mechanisms of growth, and its association, if any, with the well-documented failure to thrive seen among HIV-infected children [5] [6] [7] [8] .
SUBJECTS, MATERIALS, AND METHODS

Subjects.
Fourteen well-nourished (mean serum albumin level ‫ע‬ SD, g/L [at the first evaluation], 46 ‫ע‬ 3 g/L [at the second evaluation], and g/L 45 ‫ע‬ 2 4 5 ‫ע‬ 3 [at the third evaluation]), prepubertal, HIV-seropositive white children (6 boys and 8 girls; age range, 5-11 years) were studied. The study population consisted of randomly selected HIV-infected children who were outpatients at the Institute of Infectious Diseases, IRCCS San Matteo Hospital, University of Pavia (Pavia, Italy). Written, informed consent was obtained from each child's parent or guardian, and the protocol described in the present report was approved by the ethics committee of the Department of Internal Medicine and Medical Therapy, University of Pavia.
For all patients, HIV infection was attributed to perinatal transmission. Twelve patients had asymptomatic HIV infection or mild disease (6 had category A1 infection, 3 had category A2 infection, and 3 had category A3 infection), whereas 2 patients had severe HIV infection (1 had category B2 infection and 1 had category C2 infection), in accordance with the definitions of infection in the classification of the Centers for Disease Control and Prevention [9] . HIV infection was confirmed by ELISA, Western blot analysis, polymerase chain reaction, and viral culture. The mean CD4 + cell count ‫ע(‬ SD) was cells/L ‫ע‬ cells/L at the first 6 6 426 ϫ 10 308 ϫ 10 evaluation, cells/L ‫ע‬ cells/L at the second 6 6 625 ϫ 10 510 ϫ 10 evaluation, and cells/L ‫ע‬ cells/L at the 6 6 506 ϫ 10 328 ϫ 10 third evaluation. The mean HIV RNA level ‫ע(‬ SD) was 3.1 log 10 copies/mL ‫ע‬ 0.1 log 10 copies/mL at the first evaluation, 3.6 log 10 copies/mL ‫ע‬ 0.2 log 10 copies/mL at the second evaluation, and 3.4 log 10 copies/mL ‫ע‬ 0.2 log 10 copies/mL at the third evaluation.
No patient presented with clinical or biochemical features of hepatic or renal failure; none was affected by any neurological disease, pituitary and/or hypothalamic disease, or thyroid disease or was using medication known to interfere with hormone secretion or to be toxic to the pancreas. For all the children evaluated, serum levels of amylase and lipase were in the range considered to be normal. Four of the patients were receiving zidovudine (90-160 mg/m 2 twice daily or 3 times daily); none was receiving protease inhibitors. None of the HIV-infected children had any clinically active opportunistic infection during the month leading up to their entry into the study.
Sixteen clinically healthy sex-and age-matched children (7 boys and 9 girls; age range, 6-11 years) were chosen as the control group. None of the patients or control subjects had a family history of diabetes. Levels of physical activity in both groups of children were assessed, as were the nutrient composition of the diet and the dietary history of the children during the 3 days preceding entry into the study. Data on the height of the parents of the patients and control subjects suggested that growth potential was the same in both groups of children.
For the 2 groups of children, the following parameters were evaluated: insulin, glucagon, C-peptide, and glucose levels; lipid patterns (total cholesterol, high-density lipoprotein cholesterol, and triglycerides); and growth hormone (GH), thyroid-stimulating hormone (TSH), cortisol, and adrenocorticotropic hormone (ACTH) levels. Height and body weight were measured, and the body mass index (i.e., body weight in kilograms divided by height in meters squared) was calculated. Skinfold (biceps, triceps, suprailiac, and subscapular) thicknesses were measured twice (at 5-min intervals) at each site, by use of a Harpender skinfold caliper and by means of a standardized technique. Bone age was estimated; radiographs of the left hand were evaluated using the Greulich and Pyle method [10] , and the ratio of bone age to chronological age was calculated. Growth velocity (expressed as centimeters of growth per year) during the 12 months preceding the most recent clinical evaluation was calculated. The auxological data regarding the first evaluation were available because the children who were evaluated were attending the Institute of Infectious Disease at least every 6 months from the time of their birth. Also, weight velocity (changes in the z score used in weight-for-age data) and height velocity (changes in the z score used in height-for-age data) were calculated. All the children were prepubertal; pubertal status was assessed according to the method of Tanner and Whitehouse [11] . Evaluation of these parameters was repeated 3 times, at yearly intervals. In addition, both the HIV-infected children and the children who were control subjects had glucagon testing performed. Testing was performed at 8:00 a.m., after a 15-h fast. The serum level of glucose was determined before and at 30, 60, 90, 120, 150, and 180 min after intramuscular injection of glucagon (0.1 mg/kg) [12] . In accordance with the findings of Hughes [12] , an increase of !50% in the plasma level of glucose at 180 min after injection of glucagon was considered to be an abnormal finding. No side effects were observed during the procedure. To avoid venipuncture stress, blood samples were obtained through the use of an indwelling catheter inserted into an antecubital vein before the study. Blood samples were centrifuged immediately and were stored at Ϫ80ЊC until assayed. The ratios of insulin to glucose and insulin to glucagon were calculated, and insulin resistance was evaluated using homeostasis model assessment (HOMA) [13] . Laboratory procedures. The serum level of insulin was evaluated using double-antibody radioimmunoassay (RIA; Kabi Pharmacia Diagnostics AB) and was expressed as picomoles per liter. The intra-and interassay coefficients of variation were !6%, and the lower limit of detection was 10.7 pmol/L.
The serum level of glucagon was determined using doubleantibody RIA (DPC) and was expressed as picograms per milliliter. The intra-assay coefficient of variation was !5%; the interassay coefficients were within the range of 5%-8%. The lower limit of detection was 1.5 pg/mL.
The serum level of C-peptide was evaluated using doubleantibody RIA (Biodata Diagnostical; Biochem Immunosystems Italia) and was expressed as nanograms per milliliter. The intraassay coefficient of variation was 4.5%, and the interassay coefficient was 4.3%. The lower limit of detection was 10.1 ng/mL.
The plasma level of GH was measured using the immunoradiometric assay (Kabi Pharmacia Diagnostics AB) and was expressed as micrograms per liter. The intra-and interassay coefficients of variation of this assay were !5%, and the lower limit of detection was !0.04 mg/L.
The serum level of TSH was determined using a solid-phase 2-site fluoroimmunometric assay (Delfia TSH ultra; Wallac Oy) and was expressed as milliunits per liter. The intra-and interassay coefficients of variation were within the range of 3%-7%, and the lower limit of detection was 0.005 mU/L. The plasma level of cortisol was evaluated using solid-phase RIA (DPC) and was expressed as nanomoles per liter. The intraand interassay coefficients of variation were within the range of 3%-5.5%, and the sensitivity of the RIA was ∼5.5 nmol/L.
The plasma level of ACTH was determined using doubleantibody RIA (DPC) and was expressed as picomoles per liter. The intra-assay coefficient of variation was !9%, whereas the interassay coefficient of variation was 5%; the lower limit of detection was 1.76 pmol/L. The fasting serum level of glucose was measured using a Kodak EKtachem 700 Analyzer (Eastman Kodak).
High-density lipoprotein (HDL) cholesterol concentrations were determined using an electrophoretic and densitometric method (REP Lipoprotein-Kin; Helena Diagnostics). The Peridochrom Triglyceride GPO-PAP and the CHOD-PAP kits (Boehringer Mannheim) were used for the triglyceride and total cholesterol assays, respectively.
RIA analyses were processed with a multichannel gamma counter (Clini Gamma 1272; Wallac Oy). Fluoroimmunometric analyses were performed using a computerized fluorometer (LKB 1230 Arcus; Wallac Oy). Immunoenzymatic procedures were processed using the multichannel kinetic Analyzer Milenia (DPC).
The accuracy and precision of the methods were assessed by Lyphochek Immunoassay Control (Bio-Rad). Results were processed using Multicalc software (Kabi Pharmacia Diagnostic).
Statistical analysis. Results are expressed as median values with their respective ranges. Data were compared using the Mann-Whitney U test. The Spearman rank test was used to look for correlations among parameters.
was con-P ! .05 sidered to be statistically significant.
RESULTS
The insulin, glucagon, C-peptide, glucose, and HOMA values for the HIV-infected children were significantly higher than the values recorded for the control subjects at all 3 evaluations. Table 1 details the parameters assessed during the first, second, and third evaluations. The results of the glucagon challenge test revealed that all the healthy children had a consistently normal glycemic response, compared with the significantly impaired response noted in 11 (79%) of 14 HIV-infected children; as shown in table 1, the glycemic response thus was significantly lower in the HIV-infected children, compared with the control subjects (
). Moreover, a significant correlation was found P ! .01 between the ratio of insulin to glucagon and the growth velocity (expressed as centimeters of growth per year) of HIV-infected children at all 3 evaluations ( , ; , r p 0.83 P ! .01 r p 0.82 P ! ; and , at the first, second, and third eval-.01 r p 0.67 P ! .01 uations, respectively).
With regard to the other hormone levels assessed and the lipid pattern observed, the levels of GH, TSH, cortisol, ACTH, triglycerides, total cholesterol, and HDL cholesterol were found to be similar in the patients and the control subjects at all evaluations (table 1) . With regard to the growth parameters investigated, bone age was significantly delayed, and the ratio of , HIV-seropositive children versus sex-and age-matched P ! .01 healthy children (i.e., control subjects) (Mann-Whitney U test).
bone age to chronological age was !1 for 11 (79%) of 14 patients at all 3 evaluations. HIV-seropositive children had reduced body weight and height velocity. The HIV-seropositive patients had a markedly shorter height and reduced body weight, in comparison with the control subjects (table 2). Levels of physical activity (2 h of activity/week) and the nutrient composition of dietary intake were similar and adequate in the HIV-infected patients and the healthy children; no significant differences in diet were observed between the groups, and, indeed, the percentages of energy consumed as proteins, fats, and carbohydrates were similar. The virus loads and the CD4 + cell counts of the HIV-infected children did not correlate with any endocrine, growth, or metabolic parameters studied. No changes in any parameter were found either in the 2 children with AIDS versus the 12 HIV-infected (asymptomatic) subjects or in the 4 children receiving zidovudine versus the 10 children who were not receiving therapy.
DISCUSSION
Endocrine dysfunction has been extensively reported in HIVinfected adults [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] and children [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] ; however, at present, data documenting pancreatic function in HIV-infected children are lacking. Furthermore, there are few available data on b cell dysfunction in adult HIV-infected patients receiving treatment with protease inhibitors [4] . In effect, highly active antiretroviral therapy determined severe metabolic disturbancesnamely, insulin resistance. The etiology of this syndrome appears to be multifactorial; in addition to antiviral drugs, hypercytokinemia and HIV infection itself, including the virally encoded molecules Vpr and Tat (virion-associated accessory proteins), could contribute to the development of insulin resistance [36, 37] . Against this background, the results of the prospective study reported here constitute, to our knowledge, the first evidence of altered pancreatic endocrine secretion and its association with growth failure, which is one of the most sensitive indicators of disease progression [5] and has been extensively reported to occur in HIV-infected children [5] [6] [7] [8] . In particular, a recent study demonstrated the ability of height velocity to predict the clinical progression of infection, as well as the progression of infection as determined by laboratory values [38] . In fact, to our knowledge, the results of the present study demonstrate, for the first time, that insulin, glucagon, and C-peptide levels and insulin resistance (as evaluated by HOMA) are markedly greater among HIV-infected children than among sex-and age-matched healthy control subjects. Moreover, a close association was found between altered pancreatic endocrine secretion and failure to thrive. In particular, an association was observed between the ratio of insulin to glucagon and growth velocity at all 3 evaluations. Impairment of residual b cell function was also shown; for 11 HIVinfected children, an altered glycemic response to the glucagon test was demonstrated. Increased secretion of glucagon and the presence of insulin resistance may be key contributors to the statural and ponderal growth alterations observed in HIV-infected children. Thus, hyperglucagonemia may be one of the potential mediators of the HIV-associated catabolic state. Such derangement of pancreatic endocrine secretion may cause a shift in the metabolic pathways from anabolism to catabolism, by inducing futile substrate cycling, lipolysis, and proteolysis, probably in association with a cytokine-mediated mechanism; this shift may be one of the causes of the altered growth mechanism in HIV-infected children. Glucagon seems to be a key regulator of inflammatory cytokines that have metabolic actions [39] . Simple biochemical parameters, such as glucagon and insulin levels, could be routinely measured in consecutive clinical assessments, to document metabolic alterations that, although apparently are only secondary, may, in fact, be very important in the regulation of growth among HIV-infected children. Additional studies are needed of larger samples of HIV-seropositive children, including children who are evaluated after receiving combination therapies, to better define the role of endocrine pancreas dysfunction in the development of a growth mechanism alteration and to clarify whether therapies involving protease inhibitors are able to influence this derangement of the endocrine pancreas. Finally, the long-term consequences of these endocrine pancreatic changes and the possible influence of b cell dysfunction on lipodystrophy in individuals receiving combination therapy [2] require investigation both in adults and children.
